Adaptimmune Therapeutics currently has a consensus target price of $19.33, suggesting a potential upside of 62.88%. Curis has a consensus target price of $32.50, suggesting a potential upside of 1,778.61%. Given Curis’ higher possible upside, analysts plainly believe Curis is more favorable than Adaptimmune Therapeutics.
Adaptimmune Therapeutics beats Curis on 9 of the 13 factors compared between the two stocks.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Curis Company Profile
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts. Receive News & Ratings for Adaptimmune Therapeutics analysts' ratings for Adaptimmune Therapeutics and related companies daily email newsletter .
Saturday, June 30 2018
Critical Comparison: Adaptimmune Therapeutics (ADAP) and Curis (CRIS)
Lai Autonomous District Council huam chhunga Ngengpui Sanctuary leh Phawngpui National Park te chu LADC enkawlna hnuaia dah a nih theih nan Environment, Forest & Climate Change Deptt-ah hmalak mek niin LADC Chief Executive Member, Pu T. Zakunga’n a sawiMonday, July 16 2018
Champhai Special Court Judge, Pu R. Vanlalena’n hmeichhe naupang kum 6 mi pawngsualtu Vaphai khaw mi, Remsangpuia, kum 23 chu rim taka hnathawk chunga kum 12 chhung lung in tang tur leh pawisa Rs.3,000/- chawi turin a hremMonday, July 16 2018
Mizoram Youth Commission-in thalaite tana hma a lakna kal zelah inrinni khan pawl 11 science zirlaite tan Aizawl leh Lungleiah IIT-JEE leh NEET Online Coaching Scholarship dawng thei tur zawnna Exam a buatsaih.Monday, July 16 2018
Sorkar laipui atanga sum rawn kal Mizoram sorkar in a tum ve tur (State Matching Share) a pek loh avangin National Health Mission (NHM) in cheng vbc 49 a chan a, hei vang hian hnathawkte’n hlawh an lak theih loh phah niin kar tin chhuak chanchinbu The FronMonday, July 16 2018